RXRX logo

RXRX
Recursion Pharmaceuticals Inc

14,253
Mkt Cap
$2.1B
Volume
27.88M
52W High
$12.36
52W Low
$3.79
PE Ratio
-2.23
RXRX Fundamentals
Price
$3.85
Prev Close
$4.03
Open
$4.15
50D MA
$5.22
Beta
2.63
Avg. Volume
67.35M
EPS (Annual)
-$1.69
P/B
1.89
Loading...
Loading...
News
all
press releases
Penny Stocks To Watch Now - November 14th
Leap Therapeutics, Cypherpunk Technologies, Invivyd, Bitfarms, Beyond Meat, Strive, and Recursion Pharmaceuticals are the seven Penny stocks to watch today, according to MarketBeat's stock screener...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Equities Analysts Set Expectations for RXRX FY2025 Earnings
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) - Stock analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Recursion Pharmaceuticals in a research report...
MarketBeat·11d ago
News Placeholder
Promising Biotech Stocks To Consider - November 8th
Danaher, Vertex Pharmaceuticals, Moderna, Recursion Pharmaceuticals, argenex, United Therapeutics, and Medpace are the seven Biotech stocks to watch today, according to MarketBeat's stock screener...
MarketBeat·11d ago
News Placeholder
Promising Biotech Stocks To Add to Your Watchlist - November 7th
Danaher, Vertex Pharmaceuticals, argenex, Recursion Pharmaceuticals, Moderna, Medpace, and United Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener...
MarketBeat·12d ago
News Placeholder
Best Biotech Stocks To Consider - November 6th
Moderna, Vertex Pharmaceuticals, Danaher, Iovance Biotherapeutics, Recursion Pharmaceuticals, argenex, and Viridian Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's...
MarketBeat·13d ago
News Placeholder
Top Biotech Stocks To Follow Now - November 5th
Danaher, Vertex Pharmaceuticals, Recursion Pharmaceuticals, Moderna, and Lunai Bioworks are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are...
MarketBeat·14d ago
News Placeholder
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
Zacks·14d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +5.26% and -70.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
Zacks·17d ago
News Placeholder
Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline
Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·22d ago

Latest RXRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.